Study wrapper · #185
Sex, Not Age, Predicts Weight Loss Outcomes With Tirzepatide: A Retrospective Analysis.
Editor's note
A single-centre retrospective cohort (1,039 Mayo Clinic patients on tirzepatide for at least 12 months) asking which patient factors predict weight loss in ordinary practice. Retrospective real-world cohorts capture everyday effectiveness that trials miss, but they carry selection and confounding limits: this sample is restricted to people who stayed on therapy 12 months or more, filtering out early discontinuers and so likely flattering the average response. Within that frame, researchers reported that women lost more total body weight than men at 15 months (15.1% versus 10.7%), and that in multivariable analysis greater loss tracked with female sex, absence of type 2 diabetes, no prior obesity medication, no weight-gain-promoting co-medications, and higher tirzepatide dose, while age was not an independent predictor. The headline, sex not age, is a useful counter to an intuitive assumption, but a single-centre design and the persistence filter limit generalisability, and residual confounding (for example dose titration reflecting tolerability) is hard to exclude. Treat this as a hypothesis-refining observation for personalising expectations, not a causal rule.
Plain-language abstract
This study looked at real-world patients rather than a controlled trial, to see who loses the most weight on tirzepatide. Researchers reviewed records of 1,039 adults with overweight or obesity who started tirzepatide at the Mayo Clinic between June 2022 and May 2024 and stayed on it continuously for at least 12 months. Because only people who kept taking the drug for a year were included, the results may look better than for everyone who ever starts it. They measured the percent of total body weight lost at 15 months and compared results by sex and age group. Women lost significantly more than men (15.1% versus 10.7%). People aged 45 or under lost more than those 60 and over (15.1% versus 12.3%). When several factors were analysed together, greater weight loss was linked with being female, not having type 2 diabetes, not having used obesity medicines before, not taking other drugs that promote weight gain, and using a higher tirzepatide dose. Age on its own did not independently predict the result. The authors concluded that sex, rather than age, predicted weight loss among people who used the medicine continuously, and that sex-specific factors are worth considering when personalising treatment.